{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-024659","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.164173+00:00","generated_at":"2026-05-21T23:18:04.372547+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aquestive Q1 net loss $22.9M; cuts FY revenue guidance on Libervant setback","bullets":["Total revenue $8.7M, down 28% YoY from $12.1M; net loss $0.24/share vs $0.17 loss last year.","NDA for Anaphylm submitted; plans Q1 2026 launch if FDA approved; will not appeal Libervant court decision.","Libervant reclassified to tentative approval; sales/marketing paused; FY revenue guidance cut to $44-50M.","Non-GAAP adjusted EBITDA loss $17.6M vs $7.2M prior year; cash $68.7M.","De-emphasizing AQST-108 (alopecia) until after Anaphylm launch to focus resources."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-024659","json":"https://secwatch.observer/filing/0001628280-25-024659.json","markdown":"https://secwatch.observer/filing/0001628280-25-024659.md","text":"https://secwatch.observer/filing/0001628280-25-024659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828025024659/0001628280-25-024659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828025024659/aqst-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:18:04.372547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}